Amphastar Pharmaceuticals Advances Proprietary Pipeline with Novel Eye Drop and Cancer Therapies
Key Insights
Amphastar is transitioning from generic drugs to proprietary therapies with four new chemical entities (NCEs) showing promising preclinical and early clinical data.
AMP-107 (search) represents a potential breakthrough as the first non-injectable anti-VEGFR (search) eye drop, targeting a $9.4 billion market for wet AMD (search) and diabetic macular edema (search).
The company's oncology candidate AMP-105 (search) demonstrates a novel mechanism targeting cell growth and metastasis inhibition with broader anti-tumor activity.
Amphastar Pharmaceuticals is making significant strides in its strategic shift from generic medications to proprietary drug development, with four new chemical entities (NCEs) demonstrating promising results in preclinical and early clinical studies. The company's pipeline includes breakthrough therapies targeting major therapeutic areas including oncology and ophthalmology.
Novel Ophthalmology Treatment Shows Market Potential
AMP-107 (search) stands out as a potentially transformative therapy, described as the "first non-injectable anti-VEGFR (search) eye drop" with dual targeting of VEGFR and integrin alpha-v beta-3 (search). According to company management, this innovative approach aims to reduce treatment burden and improve compliance for patients with wet age-related macular degeneration (AMD) or diabetic macular edema (search) (DME).
The market opportunity for AMP-107 (search) appears substantial, with Zhang citing a 2024 market size estimate of $9.4 billion and noting there are "two to three million" patients with wet AMD (search) or DME. The dual-targeting mechanism represents a novel approach in ophthalmology, potentially offering advantages over current injectable treatments.
Oncology Pipeline Targets Metastasis
In oncology, AMP-105 (search) is being developed as a product with a potentially novel mechanism targeting cell growth and metastasis inhibition. Early studies have shown broader anti-tumor activity, suggesting the therapy may have applications across multiple cancer (search) types. This broad activity profile could position AMP-105 as a significant addition to the oncology treatment landscape.
Advanced Drug Conjugate Technology
AMP-109 (search) represents the company's entry into peptide drug conjugate (PDC) technology, combining a targeting peptide with docetaxel. Zhang explained that this approach is intended to improve safety by reducing toxicity while improving efficacy compared to traditional chemotherapy approaches. This technology platform could potentially be applied to other cytotoxic agents in future development programs.
Near-Term Commercial Pipeline
Beyond the novel NCEs, Amphastar has positioned itself for near-term commercial success with AMP-007 (search), a metered-dose inhaler expected to launch mid-2026 that could be the first generic in its market. The company also projects AMP-004, an insulin aspart product, for launch in 2027.
The company's strategic transformation is further supported by its Baqsimi acquisition, which management calls transformative with reiterated peak sales guidance of $250-$275 million. Management expects mid-single-digit Baqsimi growth this year and plans to exit unprofitable international markets to boost margins.